| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2000;102:2707.)
© 2000 American Heart Association, Inc.
Clinical Investigation and Reports |
From the Baker Medical Research Institute and Cardiovascular Medicine, Alfred Hospital, Melbourne, Australia.
Correspondence to Dr David M. Kaye, Molecular Neurocardiology Laboratory, Baker Medical Research Institute, Commercial Road, Prahran, Victoria 3181, Australia. E-mail david.kaye{at}baker.edu.au
BackgroundThe clinical features of congestive heart failure (CHF) result from a complex interaction between reduced ventricular function, neurohormonal activation, and impaired endothelial function. Although endothelial dysfunction has been well documented, the mechanisms that contribute to this abnormality remain unknown. Recent studies, however, indicate a potential therapeutic role for supplemental L-arginine, suggesting the presence of an underlying disorder of L-arginine metabolism.
Methods and ResultsWe used 2 complementary approaches to assess L-arginine transport in control subjects and patients with CHF. During a steady-state intra-arterial infusion of [3H]L-arginine (100 nCi/min), forearm clearance of [3H]L-arginine was significantly reduced in CHF patients compared with forearm kinetics in control subjects (64±2 versus 133±14 mL/min, P=0.002). In conjunction with this, [3H]L-arginine uptake by peripheral blood mononuclear cells (PBMCs) was also substantially reduced in heart failure patients compared with controls (Vmax 10.1±1.3 versus 49.8±7.1 pmol/105 cells per 5 minutes, P<0.001). In association with this finding, we observed a 76% (P<0.01) reduction in mRNA expression for the cationic amino acid transporter CAT-1, as assessed by ribonuclease protection assay.
ConclusionsThese data document both in vivo and in vitro evidence for a marked depression of L-arginine transport in human CHF and therefore provide an explanation for the restorative actions of supplemental L-arginine on vascular function in CHF.
Key Words: amino acids nitric oxide radioisotopes endothelium cells
This article has been cited by other articles:
![]() |
C. C. Huang, C.-B. Chiribau, M. Majumder, C.-M. Chiang, R. C. Wek, R. J. Kelm Jr., K. Khalili, M. D. Snider, and M. Hatzoglou A Bifunctional Intronic Element Regulates the Expression of the Arginine/Lysine Transporter Cat-1 via Mechanisms Involving the Purine-rich Element Binding Protein A (Pur{alpha}) J. Biol. Chem., November 20, 2009; 284(47): 32312 - 32320. [Abstract] [Full Text] [PDF] |
||||
![]() |
W.H. W. Tang, Z. Wang, L. Cho, D. M. Brennan, and S. L. Hazen Diminished global arginine bioavailability and increased arginine catabolism as metabolic profile of increased cardiovascular risk. J. Am. Coll. Cardiol., June 2, 2009; 53(22): 2061 - 2067. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. H. Wilson Tang, W. Tong, K. Shrestha, Z. Wang, B. S. Levison, B. Delfraino, B. Hu, R. W. Troughton, A. L. Klein, and S. L. Hazen Differential effects of arginine methylation on diastolic dysfunction and disease progression in patients with chronic systolic heart failure Eur. Heart J., October 2, 2008; 29(20): 2506 - 2513. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Guazzi, R. Arena, and M. D. Guazzi Evolving changes in lung interstitial fluid content after acute myocardial infarction: mechanisms and pathophysiological correlates Am J Physiol Heart Circ Physiol, March 1, 2008; 294(3): H1357 - H1364. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Yang, K. Venardos, E. Jones, B. J. Morris, J. Chin-Dusting, and D. M. Kaye Identification of a Novel Polymorphism in the 3'UTR of the L-Arginine Transporter Gene SLC7A1: Contribution to Hypertension and Endothelial Dysfunction Circulation, March 13, 2007; 115(10): 1269 - 1274. [Abstract] [Full Text] [PDF] |
||||
![]() |
W.-Z. Zhang, K. Venardos, J. Chin-Dusting, and D. M. Kaye Adverse Effects of Cigarette Smoke on NO Bioavailability: Role of Arginine Metabolism and Oxidative Stress Hypertension, August 1, 2006; 48(2): 278 - 285. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Steppan, S. Ryoo, K. H. Schuleri, C. Gregg, R. K. Hasan, A. R. White, L. J. Bugaj, M. Khan, L. Santhanam, D. Nyhan, et al. Arginase modulates myocardial contractility by a nitric oxide synthase 1-dependent mechanism PNAS, March 21, 2006; 103(12): 4759 - 4764. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Teerlink ADMA metabolism and clearance Vascular Medicine, July 1, 2005; 10(1_suppl): S73 - S81. [Abstract] [PDF] |
||||
![]() |
T. Teerlink ADMA metabolism and clearance Vascular Medicine, May 1, 2005; 10(2_suppl): S73 - S81. [Abstract] [PDF] |
||||
![]() |
M. P. Schlaich, M. M. Parnell, B. A. Ahlers, S. Finch, T. Marshall, W.-Z. Zhang, and D. M. Kaye Impaired L-Arginine Transport and Endothelial Function in Hypertensive and Genetically Predisposed Normotensive Subjects Circulation, December 14, 2004; 110(24): 3680 - 3686. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M. Parnell, J. P. F. Chin-Dusting, J. Starr, and D. M. Kaye In vivo and in vitro evidence for ACh-stimulated L-arginine uptake Am J Physiol Heart Circ Physiol, July 1, 2004; 287(1): H395 - H400. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.E.S. Miner, A. Al-Hesayen, S. Kelly, T. Benson, J.J. Thiessen, V.R. Young, and J.D. Parker L-Arginine Transport in the Human Coronary and Peripheral Circulation Circulation, March 16, 2004; 109(10): 1278 - 1283. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. P.F. Chin-Dusting, B. A. Ahlers, D. M. Kaye, J. J. Kelly, and J. A. Whitworth L-Arginine Transport in Humans With Cortisol-Induced Hypertension Hypertension, June 1, 2003; 41(6): 1336 - 1340. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. Kaye, M. M. Parnell, and B. A. Ahlers Reduced Myocardial and Systemic L-Arginine Uptake in Heart Failure Circ. Res., December 13, 2002; 91(12): 1198 - 1203. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2000 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |